Innate Pharma S.A. (IPHA)
NASDAQ: IPHA
· Real-Time Price · USD
2.11
-0.07 (-3.21%)
At close: Aug 15, 2025, 3:59 PM
2.12
0.47%
After-hours: Aug 15, 2025, 04:00 PM EDT
-3.21% (1D)
| Bid | 1.6 |
| Market Cap | 171.19M |
| Revenue (ttm) | 12.62M |
| Net Income (ttm) | -49.47M |
| EPS (ttm) | -0.71 |
| PE Ratio (ttm) | -2.97 |
| Forward PE | -71.67 |
| Analyst | Buy |
| Ask | 2.7 |
| Volume | 7,249 |
| Avg. Volume (20D) | 10,761 |
| Open | 2.22 |
| Previous Close | 2.18 |
| Day's Range | 2.04 - 2.27 |
| 52-Week Range | 1.29 - 3.51 |
| Beta | 0.93 |
About IPHA
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol IPHA
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for IPHA stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts5 months ago
+20.62%
Innate Pharma shares are trading higher after the ...
Unlock content with
Pro Subscription
8 months ago
+29.25%
Innate Pharma shares are trading higher after the company announced its TELLOMAK Phase 2 trial of Lacutamab demonstrated significant symptom relief and quality of life improvements.
2 months ago · businesswire.com
Innate Pharma Highlights Abstracts Selected for ASCO 2025 Annual MeetingMARSEILLE, France--(BUSINESS WIRE)-- #ANKET--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) announced today that four abstracts with Innate's drugs i...
3 months ago · businesswire.com
Innate Pharma Highlights ANKET® Abstracts Selected for the EHA 2025 CongressMARSEILLE, France--(BUSINESS WIRE)-- #ANKET--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that an abstract regarding IPH6501, its A...